Moberg Pharma AB   Report issue

For profit Phase 2 Phase 3
Founded: Bromma Sweden (2006)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2007
NCT01137630
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Moberg Pharma AB | MOBERG PHARMA NORTH | Moberg Pharma, Sweden

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatitis (Phase 3)

Dermatitis, Atopic (Phase 2)

Dermatitis, Seborrheic (Phase 3)

Eczema (Phase 3)

Keratosis (Phase 2)

Keratosis, Actinic (Phase 2)

Mucositis (Phase 2)

Onychomycosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 11